PAP
SLDB icon

Persistent Asset Partners’s Solid Biosciences SLDB Stock Holding History

Persistent Asset Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,990
Closed -$202K – 897
2026
Q1 		$202K Buy
+27,990
New +$180K 0.08% 192

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Persistent Asset Partners's SLDB Position: Q2 2026 in Review

Persistent Asset Partners sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 27,990 shares — an estimated $202K sold.

Persistent Asset Partners first reported a position in SLDB in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Persistent Asset Partners reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 27,990 Solid Biosciences shares in Q2 2026, an estimated $202K.
  • Persistent Asset Partners first reported a position in Solid Biosciences in Q1 2026 and held it in 1 quarter.
  • Persistent Asset Partners's Solid Biosciences position peaked at $202K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.